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Background: In studies of idiopathic pulmonary fibrosis (IPF), whites makeup the vast majority
of subjects. Whether ethnic/racial differences in idiopathic pulmonary fibrosis occur in the
general population is unknown.
Methods: To compare the presence of IPF between ethnic/racial groups of U.S. decedents
from 1989 to 2007 by using the National Center for Health Statistics database.
Results: There were 251,058 U.S. decedents with IPF; 87.2% were non-Hispanic whites (White),
5.1% were non-Hispanic African American (Black), 5.4% were Hispanic, and 2.2% were from
other ethnic/racial groups (Other). Whites coded with IPF died older than those in the other
groups (77.9 years vs. 72.1 years for Blacks, 75.3 years for Hispanics, and 75.6 years for Others;
p < 0.0001 for all pairwise comparisons). When controlling for age and for sex, compared with
Whites, both Hispanics and Others were more likely to be coded with IPF (OR Z 1.47, 95% CI
1.44e1.49, p < 0.0001 and OR Z 1.29, 95% CI 1.26e1.36, p < 0.0001 respectively), while
Blacks were significantly less likely to be coded with IPF (OR Z 0.48, 95% CI 0.47e0.49,
p < 0.0001). Among decedents with IPF, Hispanics were more likely, and Blacks were less
likely, than Whites to die from IPF (OR Z 1.24, 95% CI 1.20e1.29, p < 0.0001 and
OR Z 0.91, 95% CI 0.87e0.94, p < 0.0001).
Conclusion: From 1989 to 2007, Black decedents were lessdand Hispanics were moredlikely
than Whites to die of/with IPF. Research is needed to determine if genetic differences
between ethnic/racial groups explain these findings.
ª 2012 Elsevier Ltd. All rights reserved.e Lung Center and, Interstitial Lung Disease Program, National Jewish Health, Southside Building,
nver, CO 80206, USA. Tel.: þ1 303 398 1621; fax: þ1 303 398 1040.
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Ethnicity/race and IPF 589Introduction
Idiopathic pulmonary fibrosis (IPF), a progressive fibrosing
lung disease of unknown cause, occurs throughout the
world and is believed to equally affect every ethnic/racial
group.1 Epidemiological studies have identified certain risk
factors for the development of IPF, including cigarette
smoking and exposure to various dusts.2 Because IPF is
extremely rare in people less than 40 years old,1 and
disease rates increase with age,3 the aging process is also
believed to be key in the pathogenesis of IPF.4
Historically recognized as a rare disease, formal clinical
trials investigating potential therapies for IPF began in
earnest only within the last 15 years. For trials that have
recruited subjects from the United States (US), the racial/
ethnic makeup of the study samples has consisted over-
whelmingly of non-Hispanic whites (Whites). Whether this
difference in the ethnic/racial makeup of US trial pop-
ulations is due to differences in the background risk for the
development of IPF, unequal access to medical care and
resultant lower likelihood for members of ethnic/racial
minority groups to be diagnosed with IPF,5 or differences in
willingness to participate in treatment trials6,7 is unknown.
In a small percentage of cases, pulmonary fibrosis (PF)
occurs in two or more first-degree relatives, or clusters in
families over several generations.8 This is considered
familial interstitial pneumonia (FIP). In some cases of
familial clustering, specific genetic abnormalities and poly-
morphisms have been identified and offered as a potential
mechanistic explanation.9e13 Certain of these genetic
abnormalities have also been found in patients with sporadic
IPF.11,14 Although not yet proved, it is likely that the inci-
dence of these genetic abnormalities and polymorphisms
differs between ethnic/racial groups. In an attempt to
better understand the epidemiology of IPF, we investigated
the hypotheses that all ethnic/racial groups in the US are
equally likely to have IPF present at the time of deathdand
among those who do, equally likely to die of IPF itself.
Methods
We used analytic methodology described in detail else-
where.3,15 Please see the Online Supplement for a full
description of methods. Briefly, we used multiple cause of
death (MCOD) files, compiled and manipulated annually by
the National Center for Health Statistics (NCHS), that were
derived from all US death certificates from 1989 to 2007.
After a death certificate is filled out, the NCHS acquires
it and applies computer algorithms to it to yieldTable 1 1989e2007 U.S. decedents with IPF according to eth
compared with non-Hispanic whites.
IPF present IPF absent
White 219,020 (87.2) 31,989,804 (
Black 12,861 (5.1) 3,949,958 (
Hispanics 13,599 (5.4) 1,366,383 (
Other 5578 (2.2) 632,291 (
Values are counts (percentages of column total); ORZ odds ratio, CIZ
Hispanic African American; Other Z non-Hispanic of other racial catea standardized “record axis” for the certificate. The record
axis includes up to 20 associated causes of death, including
the ultimate underlying cause of death (UCD). We first
identified decedents with “pulmonary fibrosis” in the
record axis and then excluded those younger than 50 years
old or with accompanying codes for conditions with known
associations with PF, including any connective tissue
disease, radiation fibrosis, sarcoidosis, pneumoconiois, or
hypersensitivity pneumonitis. This allowed us to formulate
a strict definition of IPF. For full details on how we isolated
decedents with IPF, please see the Online Supplement. For
each death certificate, ethnicity/race information was re-
ported by the funeral director who acquired the informa-
tion from an informantdoften the surviving next-of-kin.16
When an informant was not available, ethnicity/race was
assigned by the funeral director on the basis of observation.
However, which of these methods was used for each
decedent is not recorded in the database. Individuals of
Hispanic ethnicitydwhether black (e.g., Dominicans) or
whitedwere categorized as Hispanic.
We used Chi-square tests to compare proportions between
groups and logistic regression to determine the risk for IPF
between different ethnic/racial groups while controlling for
potentially confounding effects of age and sex. To investigate
whether the changing definition of IPF over time might have
influenced results, we conducted an analysis after dividing
the data into two timeperiods: 1989e1999 and (from the time
the first American Thoracic Society Consensus Statement on
IPF(1) was published) 2000e2007. All data were analyzed
using SAS version 9.2 (SAS Institute; Cary, NC). Institutional
Review Board approval for this study was not required,
because all data contained in the database files have been
de-identified and are of public record.
Results
We analyzed 38,883,187 US death records from 1989 to
2007 and identified 251,058 decedents with IPF whose
ethnicity/race was known. In a total of 525,782 decedents
ethnicity/race was missing on the death certificate; 2302
had IPF. Among decedents with IPF, 87.2% were White, 5.1%
were non-Hispanic African American (Black), 5.4% were
Hispanic, and 2.2% were from other ethnic/racial groups
(Other). Fifty-three percent of IPF decedents were male,
and 47% were female. Their mean age was 77.4  9.9 years.
Compared with White decedents, Blacks were significantly
less likely, while Hispanics and Others were significantly
more likely, to have IPF coded on their death certificates
(Table 1).nicity/race and unadjusted ethno/racial-specific risk for IPF
% with IPF OR (95% CI)
84.4) 0.68 Reference
10.4) 0.32 0.47 (0.46e0.48)
3.6) 0.99 1.45 (1.43e1.48)
1.7) 0.87 1.29 (1.25e1.32)
confidence interval; WhiteZ non-Hispanic white; BlackZ non-
gory.
590 J.J. Swigris et al.White decedents with IPF were significantly older than
Blacks (77.9 years vs. 72.1 years), Hispanics (75.3 years),
and Others (75.6 years, p < 0.0001 for each comparison).
White IPF decedents were more likely to be male than
female, but Hispanic IPF decedents were more likely to be
female than male. There was no difference in the propor-
tion of male and female IPF decedents among Blacks or
Others (Table 2). While controlling for age and gender, the
effect of race was a significant predictor of dying of/with
IPF in the sample as a whole. Within subgroups defined by
age, while controlling for gender, race remained a signifi-
cant, independent predictor of dying of/with IPF (Table 3).
Compared with Whites, while controlling for gender and
age, the risks for IPF among the other three ethnic/racial
groups were the same for both time periods (1989e1999 vs.
2000e2007 for Blacks: OR Z 0.51 vs. 0.45; for Hispanics:
OR Z 1.48 vs. 1.40; for Others: OR Z 1.32 vs. 1.22).
Table 4 displays the underlying cause of death for IPF
decedents. Compared with Whites, Blacks coded with IPF
were significantly less likely to die of (as opposed to with)
IPF (OR Z 0.91, 95% CI 0.88e0.94, p < 0.0001), while
Hispanics were significantly more likely than Whites to die
of IPF (OR Z 1.24, 95% CI 1.20e1.29, p < 0.0001). Blacks
coded with IPF were significantly more likely than Whites
coded with IPF to die of pulmonary hypertension
(ORZ 2.45, 95% CI 1.90e3.17, p < 0.0001), while Hispanics
and Others were no more likely than Whites to die of
pulmonary hypertension (p Z 0.1 and 0.9 respectively).
Hispanics and Others coded with IPF were significantly less
likely, and Blacks were significantly more likely, than
Whites coded with IPF to die of lung cancer (for Hispanics:
OR Z 0.59, 95% CI 0.52e0.68, p < 0.0001; for Others:
OR Z 0.76, 95% CI 0.64e0.91, p < 0.0001; for Blacks:
OR Z 1.11, 95% CI 1.01e1.23, p < 0.0001respectively).Discussion
Between 1989 and 2007, we examined death records of
over 38 million decedents and identified 251,058 coded
with IPF. Compared with White decedents, Blacks wereTable 2 1989e2007 U.S. decedents with IPF according to ethni
IPF present
White
Females 102,214 (46.7)
Males 116,806 (53.3)
Black
Females 6526 (50.7)
Males 6335 (49.3)
Hispanics
Females 6822 (50.2)
Males 6777 (49.8)
Other
Females 2599 (46.6)
Males 2979 (53.4)
Values Z counts (percentage); IPF Z idiopathic pulmonary fibrosi
American; Other Z non-Hispanic of other racial category; CI Z confisignificantly less likely to be coded with IPF. Although the
overwhelming majority of decedents with IPF were White,
decedents in the Hispanic or Other (e.g., Native American,
Asian, or Pacific Islander) categories were significantly
more likely than White decedents (45% and 29% greater
odds respectively) to be coded with IPF. We believe this is
the first such systematic, nationwide assessment of the
ethnic/racial distribution of IPF and the first time the risk
for having IPF at the time of death has been compared
between ethnic/racial groups.
For decedents coded with IPF, we uncovered other
differences between ethnic/racial groups: although they
were less likely than Whites to be coded with IPF, Blacks
coded with IPF died younger (six years on average). Further-
more, although the proportion of decedents dying from
pulmonary hypertension (PH) was small in each group, and
the absolute differences between racial groups were not that
great (thus calling into question the clinical relevance of
these findings), Blacks coded with IPF had odds of dying from
PH that were over two-fold greater than Whites coded with
IPF. Hispanic decedents were more likely than Whites to be
codedwith IPF. Hispanics codedwith IPFwere alsomore likely
than Whites coded with IPF to be female, to die younger (on
average, 2.5 years younger than Whites coded with IPF), and
to die of IPF itself. However, Hispanics coded with IPF were
less likely than Whites coded with IPF to die of lung cancer.
The prevailing theory holds that IPF develops in indi-
viduals because of some combination of age, genetic
predisposition, and external (perhaps environmental)
factors.4 Because of the work done on people with FIP,
some of the genetic factors linked to IPF (sporadic disease)
are known; these include mutations in genes that code for
certain surfactant proteins, coding regions of telomerase
genes (resulting in shortened telomeres),9e13 and most
recently, a polymorphism in the promoter region of the
gene encoding mucin 5B.14 What is not known is whether
these (or other, yet-to-be-discovered) mutations or poly-
morphisms associated with lung fibrosis occur with equal
frequency in all peoples, regardless of ethnicity/racedor
even whether these genetic abnormalities have different
gender predilections within a given ethnic/racial group.city/race and gender.
IPF absent Odds ratio for female
sex (95% CI) p value
16,933,453 (52.5) 0.79 (0.78e0.80)
15,252,405 (47.5) <0.0001
2,030,264 (51.4) 0.97 (0.94e1.0)
1,919,694 (48.6) 0.14
659,346 (48.2) 1.08 (1.04e1.12)
707,037 (51.8) <0.0001
299,541 (47.4) 0.97 (0.92e1.02)
332,750 (52.6) 0.25
s; White Z non-Hispanic white; Black Z non-Hispanic African
dence interval.
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Ethnicity/race and IPF 591Such discoveries are eagerly awaited and will likely be
made in the not-to-distant future.
Our data raise suspicion that genetics may account for
some of the between ethnic/racial group differences we
observed. The data suggest Blacks are less likely than
Whites to develop IPF, but Blacks who do, could be char-
acterized by a different phenotype, dying younger and with
PH. An alternative explanation for the lower likelihood of
IPF (a disease linked to aging) among Black decedents is
that they die at a younger age (of competing comorbidities
like atherosclerotic heart disease and diabetes)dbefore
IPF occurs, or before it becomes severe enough to be
clinically recognized.
Like any epidemiological study, ours has limitations. By
relying on death certifiers to generate the primary data, we
can not be certaindnor could we test the fidelitydof diag-
noses. We believe by carefully excluding decedents with any
code for connective tissue disease, sarcoidosis, pneumoco-
niosis, radiation fibrosis, or hypersensitivity pneumonitis, or
decedents in age groups within which IPF rarely occurs, we
isolated a groupwho aremost likely to have a diagnosis of IPF.
The database we used does not include potentially important
variables related to health care access and utilization. For
example, health insurance status and whether a decedent
had a regular primary care providerdfactors that increase
the likelihood of being diagnosed with, and treated for,
a chronic diseasedare data not available in this set. It could
be that Blacks are simply not diagnosedwith IPF, because they
are less likely than Whites to have health insurance and thus
access to appropriate primary (and secondary) health care.
However, this does not explain why, in this study, Hispanics,
another under-served minority group, were more likely than
Whites to be coded with IPF. Indeed, from 1994 to 2004,
amongworking-aged US adults, 49% ofMexicanAmericans and
33% of other Hispanic Americans (and 25% of Blacks), but only
16% of Whites, were uninsured.17
Likewise, history of cigarette smokingda known risk
factor for IPFdis a variable not included in this dataset.
There are fewer Black than White cigarette smokers in the
US18; however, Blacks are more likely than Whites to
develop lung cancer.19 It would be interesting to know
whether the risk for IPF conferred by cigarette smoking
differs depending on ethnicity/race. Unfortunately, such
a study could not be accomplished by using this dataset.
The designations of ethnicity/race heredas is the case
for all US death certificatesdwere made by someone other
than the decedent. Although self-reported ethnicity/racial
categorizationdthe method used for the US censusdmay be
more valid than designation by another person, there
appears to be strong agreement between death certificate-
and census-derived ethnicity/race categorization: there is
greater than 99% agreement for whites, greater than 98%
agreement for blacks, and greater than 89% agreement for
Hispanics.16,20e22 Most pointedly, we would not expect
misclassification of ethnicity/race to hinge on the presence
or absence of IPF. Regardless, such non-differential
misclassification should bias estimates toward the null,
suggesting the associations between ethnicity/race and IPF
might be even stronger than we report.
Our group has asked a number of questions of the
database used in this study, but the focus of the current
study is unique. In a different study using this database, we
Table 4 Percentages of decedents with IPF in each ethno/racial group according to underlying cause of death (UCD).
PNA Stroke IPF Sepsis PH Lung CA COPD Cardiac Other
White 1.93 1.23 62.31 0.45 0.21 2.99 6.07 11.40 13.09
Black 1.69 1.26 59.98 0.81 0.52 3.30 6.05 11.16 14.77
Hispanics 2.51 0.77 67.35 0.61 0.22 1.79 5.29 8.49 12.77
Other 2.92 1.40 63.05 0.86 0.30 2.29 5.06 8.61 15.33
WhiteZ non-Hispanic white; BlackZ non-Hispanic African American; OtherZ non-Hispanic of other racial category; PNAZ infectious
pneumonia; IPFZ idiopathic pulmonary fibrosis; PHZ pulmonary hypertension; CA Z cancer; COPDZ chronic obstructive pulmonary
disease;CardiacZmyocardial infarction/ischemia, congestive heart failure, cardiomyopathy, cardiacdysrhythmia/suddencardiacdeath.
592 J.J. Swigris et al.calculated mortality rates for IPF over time among
different ethnic/racial groups.3 Although that and the
current study focus on the same disease, they address very
different issues. In the current study, we deal only with
decedents and not mortality rates, which by definition
depend on and vary with the living population (denominator
for mortality rate calculation).
Conclusions
In contrast to current beliefs, our data suggest that not all
ethnic/racial groups are equally predisposed to the devel-
opment of IPF and that when IPF is present, the natural
history may depend to some extent on the ethnicity/race of
the patient. Blacks appear significantly less likely than
Whites to develop the disease, but when IPF is present,
they die at a younger age. Hispanics are more likely than
Whites to have IPF present at the time of death. When IPF is
present, differences in the underlying cause of death
between ethnic/racial groups were also seen. Whether
genetic differences account for these differences requires
further research.
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